Home › Funds › Cypress Capital Group › ABT

Cypress Capital Group position in ABT

ABBOTT LABORATORIES · Health Care

Cypress Capital Group reported holding 54,602 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$5.4M, representing 0.49% of its reported portfolio and ranking #47 among its reported holdings. Cypress Capital Group has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)54.60K sh
Reported value held$5.40M
Portfolio Weight0.49%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Cypress Capital Group's ABT position evolved

Cypress Capital Group first disclosed a stake in ABT in Q3 2023 at 80,387 shares (US$7.8M). The position peaked in Q2 2025 at 75,820 shares, worth US$10.3M. Across 13 filings, Cypress Capital Group increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 54,602 shares valued at US$5.4M — an increase of 10,112 shares quarter over quarter.. Notable position changes include a 32% trim in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 80.39K $7.79M New
Q4 2023 78.01K $8.59M Reduce
Q1 2024 78.08K $8.88M Hold
Q2 2024 77.39K $8.04M Reduce
Q3 2024 76.65K $8.74M Reduce
Q4 2024 73.48K $8.31M Reduce
Q1 2025 74.17K $9.84M Add
Q2 2025 75.82K $10.31M Add
Q3 2025 76.49K $10.24M Add
Q4 2025 77.76K $9.74M Add
Q1 2026 65.54K $6.73M Reduce
Q2 2026 44.49K $4.04M Reduce
Q3 2026 54.60K $5.40M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Cypress Capital Group held ABT?

Cypress Capital Group has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Cypress Capital Group's current position in ABT?

As of Q3 2026, Cypress Capital Group holds 54.60K shares of ABT (ABBOTT LABORATORIES), valued at $5.40M, representing 0.49% of its reported portfolio and ranking #47.

Has Cypress Capital Group been buying or selling ABT?

In the latest 13F filing (Q3 2026), Cypress Capital Group increased its position in ABT. The position peaked in Q2 2025 at 75.82K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.